Santhera Pharmaceuticals Holding AG

LSE:0QN1 Stock Report

Market Cap: CHF 96.8m

Santhera Pharmaceuticals Holding Valuation

Is 0QN1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QN1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QN1 (CHF8.02) is trading below our estimate of fair value (CHF566.14)

Significantly Below Fair Value: 0QN1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QN1?

Key metric: As 0QN1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QN1. This is calculated by dividing 0QN1's market cap by their current earnings.
What is 0QN1's PE Ratio?
PE Ratio1.5x
EarningsCHF 62.86m
Market CapCHF 96.85m

Price to Earnings Ratio vs Peers

How does 0QN1's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QN1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.2x
BVXP Bioventix
24.2xn/aUK£195.7m
GNS Genus
142.9x37.7%UK£1.1b
C4XD C4X Discovery Holdings
2.9x-88.3%UK£30.3m
CGEN Compugen
79x-59.8%US$126.2m
0QN1 Santhera Pharmaceuticals Holding
1.5x35.4%CHF 96.8m

Price-To-Earnings vs Peers: 0QN1 is good value based on its Price-To-Earnings Ratio (1.5x) compared to the peer average (62.2x).

Price to Earnings Ratio vs Industry

How does 0QN1's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.27.0x37.0%
0QN1 Santhera Pharmaceuticals Holding
 1.5x35.4%US$108.30m
0QN1 1.5xIndustry Avg. 27.0xNo. of Companies5PE020406080100+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.27.0x37.0%
0QN1 Santhera Pharmaceuticals Holding
 1.5x35.4%US$108.30m
No more companies

Price-To-Earnings vs Industry: 0QN1 is good value based on its Price-To-Earnings Ratio (1.5x) compared to the European Biotechs industry average (27x).

Price to Earnings Ratio vs Fair Ratio

What is 0QN1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QN1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio1.5x
Fair PE Ratio22.7x

Price-To-Earnings vs Fair Ratio: 0QN1 is good value based on its Price-To-Earnings Ratio (1.5x) compared to the estimated Fair Price-To-Earnings Ratio (22.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QN1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 8.02
CHF 32.00
+298.9%
21.9%CHF 39.00CHF 25.00n/a2
Nov ’25CHF 8.69
CHF 32.00
+268.2%
21.9%CHF 39.00CHF 25.00n/a2
Oct ’25CHF 9.30
CHF 32.00
+244.1%
21.9%CHF 39.00CHF 25.00n/a2
Sep ’25CHF 9.05
CHF 34.50
+281.2%
13.0%CHF 39.00CHF 30.00n/a2
Aug ’25CHF 9.30
CHF 34.50
+271.0%
13.0%CHF 39.00CHF 30.00n/a2
Jul ’25CHF 8.63
CHF 34.50
+299.8%
13.0%CHF 39.00CHF 30.00n/a2
Jan ’25CHF 9.81
CHF 71.00
+623.8%
57.7%CHF 112.00CHF 30.00n/a2
Dec ’24CHF 9.21
CHF 70.00
+659.7%
60.0%CHF 112.00CHF 28.00n/a2
Nov ’24CHF 10.83
CHF 70.00
+546.3%
60.0%CHF 112.00CHF 28.00CHF 8.692
Oct ’24CHF 8.34
CHF 68.00
+715.3%
64.7%CHF 112.00CHF 24.00CHF 9.302
Sep ’24CHF 8.78
CHF 68.00
+674.3%
64.7%CHF 112.00CHF 24.00CHF 9.052
Aug ’24CHF 8.52
CHF 68.00
+698.5%
64.7%CHF 112.00CHF 24.00CHF 9.302
Feb ’24CHF 8.79
CHF 88.00
+901.1%
54.5%CHF 136.00CHF 40.00CHF 9.352
Jan ’24CHF 14.02
CHF 88.00
+527.7%
54.5%CHF 136.00CHF 40.00CHF 9.812

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

1.3%

1Y

-23.5%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-13.4%

1Y

17.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.0%

1Y

13.3%